Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MIRA
stocks logo

MIRA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.050
-64.29%
--
--
0.000
-100%
--
--
0.000
-100%
Estimates Revision
The market is revising No Change the revenue expectations for MIRA Pharmaceuticals, Inc. (MIRA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.71%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Up
up Image
+5.71%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for MIRA Pharmaceuticals Inc (MIRA.O) is -2.88, compared to its 5-year average forward P/E of -3.86. For a more detailed relative valuation and DCF analysis to assess MIRA Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.86
Current PE
-2.88
Overvalued PE
-0.22
Undervalued PE
-7.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.05
Undervalued EV/EBITDA
-2.09

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MIRA News & Events

Events Timeline

(ET)
2025-10-24
07:33:17
Mira Pharmaceuticals Launches Phase 1 MAD Study for Oral Ketamir-2
select
2025-10-16 (ET)
2025-10-16
07:38:53
Mira Pharmaceuticals Reveals Preclinical Findings for Oral Mira-55
select
2025-09-30 (ET)
2025-09-30
07:41:21
Mira Pharmaceuticals Completes Acquisition of SKNY Pharmaceuticals
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.5
07-03Benzinga
US Stocks Likely To Open Higher As Trump Announces Vietnam Trade Deal: S&P 500's Golden Cross 'Reason To Expect Better Than Average Returns,' Says Expert

  • U.S. Stock Market Update: U.S. stock futures rose slightly following President Trump's announcement of a trade deal with Vietnam, while the Nasdaq and NYSE will have early closures for Independence Day. The S&P 500 reached a record high, driven by gains in materials, technology, and energy sectors, despite a decline in private sector jobs reported by ADP.

  • Corporate Highlights: Notable stock movements included a 21% surge for Greenbrier Companies after strong earnings, while Franklin Covey dropped 7.82% due to disappointing results. Xponential Fitness saw an 18.63% increase after an SEC investigation concluded without action, and Global Interactive Technologies skyrocketed 223.31% amid significant corporate changes.

[object Object]
Preview
2.0
07-03Benzinga
Why Datadog Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket

  • Datadog's S&P 500 Inclusion: Datadog Inc's shares rose 10.6% in pre-market trading after the announcement of its inclusion in the S&P 500 index, effective July 9, 2025, replacing Juniper Networks.

  • Pre-Market Stock Movements: Several stocks experienced significant movements in pre-market trading, with Global Interactive Technologies surging 217.7% and Fly-E Group tumbling 25.8% following a reverse stock split announcement.

[object Object]
Preview
9.0
07-03Benzinga
MIRA Pharmaceuticals' Marijuana Analog Mira-55 Shows Potent Pain Relief In Preclinical Study, Stock Jumps 50% After Hours

  • MIRA Pharmaceuticals Stock Surge: MIRA Pharmaceuticals' stock price jumped approximately 50.8% to $1.87 after the announcement of Mira-55, a synthetic marijuana analog that provides pain relief comparable to morphine without psychoactive effects.

  • Regulatory Advancements and Future Prospects: The DEA confirmed that Mira-55 is not a controlled substance, facilitating its clinical development, while the company also progresses with other pain management therapies and an acquisition aimed at enhancing its market position.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is MIRA Pharmaceuticals Inc (MIRA) stock price today?

The current price of MIRA is 1.48 USD — it has increased 2.78 % in the last trading day.

arrow icon

What is MIRA Pharmaceuticals Inc (MIRA)'s business?

MIRA Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of therapeutics for neurologic, neuropsychiatric, and metabolic disorders. The Company's pipeline includes oral drug candidates designed to address significant unmet medical needs in neuropathic pain, inflammatory pain, obesity, addiction, anxiety, and cognitive decline. It holds exclusive license rights in the United States, Canada and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in neuropathic and inflammatory pain, as well as neuropsychiatric and neurocognitive disorders. Its pipeline also includes SKNY-1, a next-generation oral therapy candidate for obesity and smoking cessation. Ketamir-2 is a patent-pending oral ketamine analog evaluated for the treatment of diabetic neuropathy and is in an ongoing Phase I clinical trial.

arrow icon

What is the price predicton of MIRA Stock?

Wall Street analysts forecast MIRA stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MIRA is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is MIRA Pharmaceuticals Inc (MIRA)'s revenue for the last quarter?

MIRA Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is MIRA Pharmaceuticals Inc (MIRA)'s earnings per share (EPS) for the last quarter?

MIRA Pharmaceuticals Inc. EPS for the last quarter amounts to -1.18 USD, increased 742.86 % YoY.

arrow icon

What changes have occurred in the market's expectations for MIRA Pharmaceuticals Inc (MIRA)'s fundamentals?

The market is revising No Change the revenue expectations for MIRA Pharmaceuticals, Inc. (MIRA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by 5.71%.
arrow icon

How many employees does MIRA Pharmaceuticals Inc (MIRA). have?

MIRA Pharmaceuticals Inc (MIRA) has 3 emplpoyees as of December 05 2025.

arrow icon

What is MIRA Pharmaceuticals Inc (MIRA) market cap?

Today MIRA has the market capitalization of 60.30M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free